Half-year Report
RNS Number : 3517Q
Adams PLC
29 November 2016
Adams PLC
("Adams" or the "Company")
Interim Results for the Six Months ended 30 September 2016
Adams Plc (AIM: ADA), an investing company focusing on the technology and life sciences sectors, is pleased to announce its unaudited interim results for the six months ended 30 September 2016.
Chairman's statement
Adams generated a gross investment return of 127,000 in the six months ended 30 September 2016, which resulted in profit after tax of 24,000 after deduction of overheads and other costs. This compares to an investment return of 24,000 in the half year to 30 September 2015 and with a corresponding loss after tax of 95,000.
During the six months ended 30 September 2016, the Company spent 110,000 on a new quoted investment which was subsequently exchanged for shares and loan notes in a private company under the terms of a recommended acquisition offer. In addition, the Company generated cash proceeds of 65,000 from the partial realisation of an existing investment.
Adams currently holds 5 investments of which are 4 are quoted and 1 is unquoted, and for which the total investment carrying value at 30 September 2016 was 1,037,000 (31 March 2016: 871,000 represented by 4 quoted holdings).
The Company held cash balances of 96,000 at 30 September 2016, compared to cash balances of 258,000 at the previous 31 March 2016 year end. Net assets attributable to holders of Adams at 30 September 2016 were 1,124,000 versus 1,100,000 at 31 March 2016.
Business model
Adams is an investment company focused on targeting businesses in the technology and life sciences sectors which present opportunities for value creation, but will also consider investments in other sectors where appropriate.
Investments
The 4 listed investments currently held by the Company comprise GVC Holdings Plc, Oxford Pharmascience Group Plc, Imagination Technologies Group Plc and Communisis Plc. In addition, the Company holds shares and loan notes in unquoted Sherwood Holdings Limited, which completed the acquisition of Source Bioscience Plc as its principal asset in September 2016.
GVC Holdings Plc is a global online gaming and sports betting company with a solid on-line platform technology from which it operates some of the leading brands in the gaming sector including bwin, sporting bet, partypoker and foxy bingo.
Oxford Pharmascience Group Plc is a drug development company that re-develops approved drugs to make them better, safer and easier to take and it has a current focus to develop improved formulations of non-steroidal anti-inflammatory drugs (NSAIDs) and statins for global markets.
Imagination Technologies Group Plc is a global technology leader whose products include the key multimedia, communications and general purpose processors needed to power all mobile, consumer, automotive, enterprise and embedded electronics.
Communisis Plc is a leading provider of outsourced digital asset management and personalised customer communication services.
Source Bioscience Plc is an international provider of state of the art laboratory services and products and has an expertise in clinical diagnostics, genomics, proteomics, drug discovery & development research and analytical testing services.
Outlook
Financial markets were in recovery mode during the six-month reporting period to 30 September 2016, following the sharp falls in the early part of the year consequent to disappointing manufacturing data from China which also adversely impacted oil and commodity prices. The potential for volatility in capital markets remains given the continued economic uncertainty in the Eurozone post the Brexit vote and given that Donald Trump's victory in the US presidential elections will have implications for the whole global economy.
The Board will, therefore, continue to maintain a highly selective investment approach in these uncertain and challenging markets.
Michael Bretherton
Chairman
29 November 2016
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014
Enquiries:
| Adams plc | |
| Mike Bretherton | Tel: +44 1534 719 760 |
| Nomad - Cairn Financial Advisers LLP | |
| Sandy Jamieson, James Caithie | Tel: +44 207 148 7900 |
| Broker - Peterhouse Corporate Finance Limited | |
| Heena Karani | Tel: +44 207 469 3393 |
| 6 months ended 30 Sep 2016 | Year ended 31 Mar 2016 | 6 months ended 30 Sep 2015 | ||
| Note | (Unaudited) | (Audited) | (Unaudited) | |
| '000 | '000 | '000 | ||
| Gain on investments | 5 | 121 | 30 | 24 |
| Dividend income | 5 | 6 | - | - |
| Gross investment return | 127 | 30 | 24 | |
| Expenses | ||||
| Net foreign exchange loss | (15) | (45) | (3) | |
| Administrative expenses | (88) | (219) | (116) | |
| Operating profit/(loss) | 24 | (234) | (95) | |
| Profit/(loss) on ordinary activities before taxation | 24 | (234) | (95) | |
| Tax on profit/(loss) on ordinary activities | - | - | - | |
| Profit/(loss) for the period | 24 | (234) | (95) | |
| Total comprehensive income/(loss) for the period | 24 | (234) | (95) | |
| Earnings/(loss) per ordinary share | ||||
| Basic and diluted | 10 | 0.06c | (0.72)c | (0.40)c |
| As at 30 Sep 2016 | As at 31 Mar 2016 | As at 30 Sep 2015 | |||
| (Unaudited) | (Audited) | (Unaudited) | |||
| Note | '000 | '000 | '000 | ||
| Assets | |||||
| Non-current assets | |||||
| Investments | 6 | 1,037 | 871 | 247 | |
| Current assets | |||||
| Trade and other receivables | 7 | 8 | 3 | 5 | |
| Cash and cash equivalents | 96 | 258 | 1,012 | ||
| 104 | 261 | 1,017 | |||
| Total assets | 1,141 | 1,132 | 1,264 | ||
| Liabilities | |||||
| Current liabilities | |||||
| Trade and other payables | 8 | (17) | (32) | (25) | |
| Total liabilities | (17) | (32) | (25) | ||
| Net current assets | 87 | 229 | 992 | ||
| Net assets | 1,124 | 1,100 | 1,239 | ||
| Equity | |||||
| Called up share capital | 9 | 413 | 413 | 413 | |
| Share premium | 9 | 1,116 | 1,116 | 1,116 | |
| Retained earnings deficit | (405) | (429) | (290) | ||
| Total shareholder equity | 1,124 | 1,100 | 1,239 | ||
| Share Capital | Share Premium | Retained Earnings Deficit | Total | ||
| '000 | '000 | '000 | '000 | ||
| At 1 April 2015 | 231 | 214 | (195) | 250 | |
| Issue of shares | 182 | 902 | - | 1,084 | |
| Total comprehensive loss for period | - | - | (95) | (95) | |
| At 30 September 2015 | 413 | 1,116 | (290) | 1,239 | |
| Total comprehensive loss for period | - | - | (139) | (139) | |
| At 31 March 2016 | 413 | 1,116 | (429) | 1,100 | |
| Total comprehensive gain for period | - | - | 24 | 24 | |
| At 30 September 2016 | 413 | 1,116 | (405) | 1,124 |
| 6 months ended 30 Sep 2016 | Year ended 31 Mar 2016 | 6 months ended 30 Sep 2015 | |
| (Unaudited) | (Audited) | (Unaudited) | |
| '000 | '000 | '000 | |
| Profit/(loss) for the period | 24 | (234) | (95) |
| Unrealised (gain)/loss on revaluation of investments | (107) | 32 | (4) |
| Realised gain on disposal of investments | (14) | (62) | (20) |
| (Increase)/decrease in trade and other receivables | (5) | 7 | 5 |
| (Decrease) in trade and other payables | (15) | (60) | (67) |
| Net cash outflows from operating activities | (117) | (317) | (181) |
| Cash flows from investing activities | |||
| Proceeds from sales of investments | 65 | 357 | 193 |
| Purchase of investments | (110) | (1,024) | (242) |
| Net cash used in investing activities | (45) | (667) | (49) |
| Cash flows from financing activities | |||
| Issue of ordinary share capital | - | 182 | 182 |
| Issue of premium share capital | - | 902 | 902 |
| Net cash generated from financing activities | - | 1,084 | 1,084 |
| Net (decrease)/increase in cash and cash equivalents | (162) | 100 | 854 |
| Cash and cash equivalents at beginning of period | 258 | 158 | 158 |
| Cash and cash equivalents at end of period | 96 | 258 | 1,012 |
| 6 months ended 30 Sep 2016 | Year ended 31 Mar 2016 | 6 months ended 30 Sep 2015 | |
| '000 | '000 | '000 | |
| Unrealised gain/(loss) on investments | 107 | (32) | 4 |
| Realised gain on investments | 14 | 62 | 20 |
| Total gain on investments | 121 | 30 | 24 |
| Dividend income | 6 | - | - |
| Gross investment return | 127 | 30 | 24 |
| Quoted Equity Shares | Unquoted Equity Shares | Unquoted Loan Notes | Total | ||
| '000 | '000 | '000 | '000 | ||
| Fair value at 31 March 2015 | 174 | - | - | 174 | |
| Additions at cost | 242 | - | - | 242 | |
| Disposals | (173) | - | - | (173) | |
| Unrealised gain on the revaluation of investments | 4 | - | - | 4 | |
| Fair value at 30 September 2015 | 247 | - | - | 247 | |
| Additions at cost | 782 | - | - | 782 | |
| Disposals | (122) | - | - | (122) | |
| Unrealised loss on the revaluation of investments | (36) | - | - | (36) | |
| Fair value at 31 March 2016 | 871 | - | - | 871 | |
| Additions at cost | 110 | - | - | 110 | |
| Disposals | (51) | - | - | (51) | |
| Transfer exchange* | (103) | 6 | 97 | - | |
| Unrealised gain on the revaluation of investments | 107 | - | - | 107 | |
| Fair value at 30 September 2016 | 934 | 6 | 97 | 1,037 | |
| As at 30 Sep 2016 | As at 31 Mar 2016 | As at 30 Sep 2015 | |||
| '000 | '000 | '000 | |||
| Prepayments and accrued income | 8 | 3 | 5 | ||
| 8 | 3 | 5 | |||
| As at 30 Sep 2016 | As at 31 Mar 2016 | As at 30 Sep 2015 | |
| '000 | '000 | '000 | |
| Trade payables | 12 | 14 | 12 |
| Accruals | 5 | 18 | 13 |
| 17 | 32 | 25 |
| Ordinary shares of 0.01 | Number of shares issued and fully paid up | Share capital '000 | Share premium '000 |
| At 1 April 2015 | 23,094,798 | 231 | 214 |
| Issue of shares | 6,928,406 | 69 | 81 |
| At 30 September 2015, 31 March 2016 and 30 September 2016 | 41,276,616 | 413 | 1,116 |
| 6 months ended 30 Sep 2016 | Year ended 31 Mar 2016 | 6 months ended 30 Sep 2015 | |
| Profit/(loss) after tax attributable to equity holders of the Company ('000) | 24 | (234) | (95) |
| Weighted average number of ordinary shares | 41,276,616 | 32,559,306 | 23,889,632 |
| Basic and diluted earnings/(loss) per share | 0.06c | (0.72)c | (0.40)c |